| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.73 [0.64, 0.84] | | < 1 | | 0% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.68 [0.57, 0.81] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| PFS (extension) | 0.61 [0.53, 0.70] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.56 [0.50, 0.63] | | < 1 | | 0% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 4.51 [3.21, 6.32] | | > 1 | | 29% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| STRAE (any grade) | 0.65 [0.46, 0.92] | | < 1 | | 0% | 2 studies (2/-) | 99.3 % | some concern | not evaluable | moderate | non important | - |
| STRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.96 [0.61, 1.51] | | < 1 | | 75% | 4 studies (4/-) | 56.4 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.66 [0.48, 0.89] | | < 1 | | 37% | 4 studies (4/-) | 99.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 1.40 [0.23, 8.60] | | < 1 | | 0% | 4 studies (4/-) | 35.9 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (any grade) | 1.05 [0.74, 1.50] | | < 1 | | 0% | 4 studies (4/-) | 39.0 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 1.92 [0.84, 4.37] | | < 1 | | 0% | 4 studies (4/-) | 6.1 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Alopecia TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.25 [0.05, 1.30] | | < 1 | | 36% | 4 studies (4/-) | 95.0 % | some concern | not evaluable | moderate | non important | - |
| Arthralgia TRAE (grade 3-4) | 0.95 [0.19, 4.70] | | < 1 | | 0% | 4 studies (4/-) | 52.7 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.57 [0.15, 2.25] | | < 1 | | 0% | 4 studies (4/-) | 78.8 % | some concern | not evaluable | moderate | non important | - |
| Chills TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 0.38 [0.15, 0.93] | | < 1 | | 33% | 4 studies (4/-) | 98.3 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Cough TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Diabetes TRAE (grade 3-4) | 1.85 [0.06, 55.43] | | < 1 | | 0% | 1 study (1/-) | 36.3 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.71 [0.35, 1.44] | | < 1 | | 0% | 4 studies (4/-) | 82.8 % | some concern | not evaluable | moderate | non important | - |
| Dry skin TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea TRAE (grade 3-4) | 0.70 [0.08, 6.00] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.35 [0.15, 0.82] | | < 1 | | 0% | 4 studies (4/-) | 99.2 % | some concern | not evaluable | moderate | non important | - |
| Headache TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.18 [0.85, 11.84] | | < 1 | | 0% | 4 studies (4/-) | 4.3 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.63 [0.10, 3.88] | | < 1 | | 0% | 4 studies (4/-) | 69.0 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 0.58 [0.13, 2.67] | | < 1 | | 0% | 4 studies (4/-) | 75.7 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.16 [0.18, 7.66] | | < 1 | | 0% | 4 studies (4/-) | 43.8 % | some concern | not evaluable | moderate | non important | - |
| Increase AST TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.35 [0.05, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 85.7 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.07 [0.01, 0.50] | | < 1 | | 0% | 2 studies (2/-) | 99.5 % | some concern | not evaluable | moderate | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.09 [0.22, 5.44] | | < 1 | | 0% | 4 studies (4/-) | 45.6 % | some concern | not evaluable | moderate | non important | - |
| Myalgia TRAE (grade 3-4) | 0.94 [0.22, 4.02] | | < 1 | | 0% | 4 studies (4/-) | 53.2 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.29 [0.07, 1.29] | | < 1 | | 0% | 4 studies (4/-) | 94.7 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.18 [0.04, 0.96] | | < 1 | | 0% | 4 studies (4/-) | 97.7 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.42 [0.11, 18.63] | | < 1 | | 0% | 2 studies (2/-) | 39.4 % | some concern | not evaluable | moderate | non important | - |
| Paraesthesia TRAE (grade 3-4) | 0.63 [0.10, 3.88] | | < 1 | | 0% | 4 studies (4/-) | 69.0 % | some concern | not evaluable | moderate | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.24 [0.03, 2.13] | | < 1 | | 0% | 2 studies (2/-) | 89.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.52 [0.32, 7.22] | | < 1 | | 0% | 4 studies (4/-) | 29.8 % | some concern | not evaluable | moderate | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.92 [0.06, 14.79] | | < 1 | | 0% | 2 studies (2/-) | 52.3 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 0.94 [0.13, 6.69] | | < 1 | | 0% | 4 studies (4/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.18 [0.03, 1.07] | | < 1 | | 0% | 2 studies (2/-) | 97.0 % | some concern | not evaluable | moderate | non important | - |
| Uveitis TRAE (grade 3-4) | 1.17 [0.18, 7.68] | | < 1 | | 0% | 4 studies (4/-) | 43.7 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.96 [0.06, 15.38] | | < 1 | | 0% | 2 studies (2/-) | 51.2 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.38 [0.10, 1.43] | | < 1 | | 0% | 4 studies (4/-) | 92.4 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 0.46 [0.04, 5.09] | | < 1 | | 0% | 2 studies (2/-) | 73.5 % | some concern | not evaluable | moderate | non important | - |
